Company Secures $3 Million Additional Investment from David Lazar
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
The Company announce that David Lazar, a significant shareholder and strategic supporter, has pre-funded the second tranche in the amount of $3,000,000, pursuant to a previously announced private placement contemplated by that certain securities purchase agreement between the Company and Mr. Lazar, dated February 13, 2026. As previously disclosed, the consummation of the second tranche transactions and the issuance of the shares of series D preferred stock and series E preferred stock in connection therewith are subject to certain customary closing conditions, as well as receipt of approval by the shareholders of the Company. As a result of this additional funding, the Company has now received a total of $6,000,000 from Mr. Lazar under this commitment.
Trade with 70% Backtested Accuracy
Stop guessing
"Should I Buy QUCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QUCY
Wall Street analysts forecast QUCY stock price to rise
Wall Street analysts forecast QUCY stock price to rise
Current: 0.469
Current: 0.469
No data
About QUCY
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
